Literature DB >> 7731171

Modulation of experimental mesangial proliferative nephritis by interferon-gamma.

R J Johnson1, D Lombardi, E Eng, K Gordon, C E Alpers, P Pritzl, J Floege, B Young, J Pippin, W G Couser.   

Abstract

The observation that interferon-gamma (IFN-gamma) inhibits cell proliferation and collagen synthesis of a variety of cell types in culture has suggested that IFN-gamma may be useful in the treatment of fibroproliferative diseases. We administered recombinant IFN-gamma subcutaneously (10(5) U/kg/day for 3 days) to rats, beginning one day after the induction of mesangial proliferative nephritis with anti-Thy 1 antibody. IFN-gamma reduced glomerular (primarily mesangial) cell proliferation by 44% at days 2 and 4 compared to vehicle injected control rats with anti-Thy 1 nephritis (that is, proliferating cells that excluded the macrophage marker, ED-1, P < 0.001). Despite the inhibition of mesangial cell proliferation, IFN-gamma did not reduce the overall extracellular matrix deposition (by silver stain) or deposition of type IV collagen or laminin (by immunostaining) at 4 or 7 days, and glomerular type IV collagen and laminin mRNA levels were increased (1.4 and 1.7-fold) at 4 days relative to controls. The inability of IFN-gamma treatment to reduce mesangial matrix expansion may relate to the fact that IFN-gamma treated rats had a twofold increase in glomerular macrophages (that is, ED-1 positive cells, P < 0.001 at 2 and 4 days) with an increase in oxidant producing cells (day 2, P < 0.05) and a 1.6-fold increase in glomerular TGF-beta mRNA expression (4 days). This suggests that the effect of IFN-gamma to inhibit mesangial cell proliferation in glomerulonephritis may be offset by the ability of IFN-gamma to increase glomerular macrophages and TGF-beta expression. These data also show that IFN-gamma can partly dissociate the mesangial proliferative response from the extracellular matrix expansion in glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731171     DOI: 10.1038/ki.1995.7

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis.

Authors:  A R Kitching; M Katerelos; S J Mudge; P G Tipping; D A Power; S R Holdsworth
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  Distinctive role of Stat3 and Erk-1/2 activation in mediating interferon-gamma inhibition of TGF-beta1 action.

Authors:  Myrto Giannopoulou; Steven C Iszkula; Chunsun Dai; Xiaoyue Tan; Junwei Yang; George K Michalopoulos; Youhua Liu
Journal:  Am J Physiol Renal Physiol       Date:  2005-12-06

3.  Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV.

Authors:  Y Tsuboi; S J Shankland; J P Grande; H J Walker; R J Johnson; T P Dousa
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

4.  SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro.

Authors:  R H Pichler; J A Bassuk; C Hugo; M J Reed; E Eng; K L Gordon; J Pippin; C E Alpers; W G Couser; E H Sage; R J Johnson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

5.  Dissociation of glomerular hypertrophy, cell proliferation, and glomerulosclerosis in mouse strains heterozygous for a mutation (Os) which induces a 50% reduction in nephron number.

Authors:  C He; C Esposito; C Phillips; R K Zalups; D A Henderson; G E Striker; L J Striker
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

6.  Metalloprotease meprin beta in rat kidney: glomerular localization and differential expression in glomerulonephritis.

Authors:  Beatrice Oneda; Nadège Lods; Daniel Lottaz; Christoph Becker-Pauly; Walter Stöcker; Jeffrey Pippin; Maya Huguenin; Daniel Ambort; Hans-Peter Marti; Erwin E Sterchi
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.